Global CAR T Cell Therapy Market: Rise in the number of cell therapy clinical trials is expected to drive market growth during the forecast period

In this Market Research Future (MRFR) market note, the global CAR T Cell therapy market is discussed at length. MRFR forecasts a CAGR of 58.52% for the global CAR T Cell Therapy Market Size from 2019 to 2025. Chimeric Antigen Receptor (CAR) T Cell Therapy is an immunotherapy used for cancer treatment. In this therapy, T cells from patient body are isolated and inserted in the CAR gene so that the gene for the specific receptor binds to a certain protein on the patient’s cancer cells.

Growing prevalence of cancer across the world, technological advancement for advanced & reliable treatment for cancer, and rise in the number of cell therapy clinical studies are driving the growth of the global CAR T Cell Therapy market. According to the National Cancer Institute, it is estimated that 1,735,350 new cases of cancer were diagnosed, and 609,640 deaths were reported in the US in 2018. Moreover, the growing pharmaceutical industry is also expected to boost market growth.

Company Landscape

Novartis AG (Switzerland), Pfizer, Inc. (US), Kite Pharma (US), Cellectis (France), Autolus Therapeutics PLC (UK), CARsgen Therapeutics (China), Juno Therapeutics (US), Sorrento Therapeutics (US), Legend Biotech (US), Mustang Bio (US) are some of the key companies operating in the market.

Market Segmentation 

The MRFR report provides a complete segmental analysis of the CAR-T cell therapy market report on the basis of target antigen and application. 

Based on target antigen, the CAR-T cell therapy market is segmented into CD22, CD19, and others. Of these, the CD19 target antigen segment will have the largest share in the market over the forecast period. 

Based on application, the CAR-T cell therapy market is segmented into diffuse large B-cell lymphoma, acute lymphoblastic leukemia, and others. 

The CD19 target antigen segment will remain the largest target antigen type in the global CAR T cell therapy market

The CD19 target antigen segment accounted for a market value of USD 342.56 million in 2018. Increase in the number of clinical trials for CD19 antigens is expected to drive the growth of the segment.

The diffuse large B-cell lymphoma segment would dominate the application segment in the global CAR T cell therapy market

The diffuse large B-cell lymphoma (DLBCL) segment accounted for a value of USD 293.38 million in 2018. The increasing incidence of DLBCL and product approvals by regulatory bodies across the globe is anticipated to boost the market growth of hospitals during the assessment period.

Browse More Information:- https://www.marketresearchfuture.com/reports/car-t-cell-therapy-market-8102 

Europe CAR T Cell therapy market to exhibit the second largest market

Europe is the second largest market with a CAGR of 51.36% for CAR T cell therapy. The region held a share of 9.15% in the global CAR T cell therapy market in 2018. The increase in the occurrences of hematologic cancer such as leukemia, lymphoma, and multiple myeloma are the main factors boosting the growth of the market. Moreover, the rise in research funding and activities related to CAR-T cell therapy is anticipated to fuel the growth of the market.